NO329384B1 - Aminoindazolderivater, fremstilling derav samt farmasoytiske preparater og medisinske produkter inneholdende forbindelsene - Google Patents

Aminoindazolderivater, fremstilling derav samt farmasoytiske preparater og medisinske produkter inneholdende forbindelsene Download PDF

Info

Publication number
NO329384B1
NO329384B1 NO20044137A NO20044137A NO329384B1 NO 329384 B1 NO329384 B1 NO 329384B1 NO 20044137 A NO20044137 A NO 20044137A NO 20044137 A NO20044137 A NO 20044137A NO 329384 B1 NO329384 B1 NO 329384B1
Authority
NO
Norway
Prior art keywords
indazol
chloro
butanamide
indazole
amino
Prior art date
Application number
NO20044137A
Other languages
English (en)
Norwegian (no)
Other versions
NO20044137L (no
Inventor
Gilles Dutruc-Rosset
Dominique Le Suisse
Thomas Rooney
Franck Halley
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of NO20044137L publication Critical patent/NO20044137L/no
Publication of NO329384B1 publication Critical patent/NO329384B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20044137A 2002-03-11 2004-09-29 Aminoindazolderivater, fremstilling derav samt farmasoytiske preparater og medisinske produkter inneholdende forbindelsene NO329384B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0202997A FR2836915B1 (fr) 2002-03-11 2002-03-11 Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
PCT/FR2003/000752 WO2003078403A2 (fr) 2002-03-11 2003-03-07 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase

Publications (2)

Publication Number Publication Date
NO20044137L NO20044137L (no) 2004-11-25
NO329384B1 true NO329384B1 (no) 2010-10-11

Family

ID=27763685

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044137A NO329384B1 (no) 2002-03-11 2004-09-29 Aminoindazolderivater, fremstilling derav samt farmasoytiske preparater og medisinske produkter inneholdende forbindelsene

Country Status (30)

Country Link
US (1) US6949579B2 (pt)
EP (1) EP1487804B1 (pt)
JP (2) JP4648630B2 (pt)
KR (1) KR101068770B1 (pt)
CN (2) CN1656078A (pt)
AR (1) AR038915A1 (pt)
AU (1) AU2003242809B8 (pt)
BR (1) BR0308373A (pt)
CA (1) CA2478542C (pt)
FR (1) FR2836915B1 (pt)
GT (1) GT200300057A (pt)
HR (1) HRP20040824B1 (pt)
IL (2) IL163831A0 (pt)
JO (1) JO2326B1 (pt)
MA (1) MA27230A1 (pt)
ME (2) MEP16108A (pt)
MX (1) MXPA04007478A (pt)
MY (1) MY138269A (pt)
NO (1) NO329384B1 (pt)
NZ (1) NZ535147A (pt)
PA (1) PA8568301A1 (pt)
PE (1) PE20040155A1 (pt)
PL (1) PL370478A1 (pt)
RS (1) RS52396B (pt)
RU (1) RU2345070C2 (pt)
SV (1) SV2003001494A (pt)
TW (1) TWI329103B (pt)
UY (1) UY27713A1 (pt)
WO (1) WO2003078403A2 (pt)
ZA (1) ZA200406687B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2836914B1 (fr) * 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MXPA04011417A (es) * 2002-05-17 2005-02-14 Pharmacia Italia Spa Derivados de aminoindazol activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden.
BR0314098A (pt) 2002-09-05 2005-07-19 Aventis Pharma Sa Derivados da aminoindazóis a tìtulo de medicamentos e composições farmacêuticas que os contêm
CA2507074A1 (en) * 2002-12-02 2004-06-17 F. Hoffmann-La Roche Ag Indazole derivatives as crf antagonists
FR2848554A1 (fr) * 2002-12-12 2004-06-18 Aventis Pharma Sa Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
WO2004062662A1 (fr) 2002-12-12 2004-07-29 Aventis Pharma S.A. Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2005077912A1 (ja) * 2004-02-12 2005-08-25 Mitsubishi Pharma Corporation インダゾール化合物及びその医薬用途
FR2871158A1 (fr) * 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
RU2007101488A (ru) 2004-08-03 2008-09-10 Вайет (Us) Индазолы для лечения сердечно-сосудистых заболеваний
WO2007032936A2 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
ATE542800T1 (de) 2006-01-31 2012-02-15 Array Biopharma Inc Kinasehemmer und ihre anwendungsverfahren
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
CN101594862B (zh) * 2006-12-20 2015-11-25 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代吲唑衍生物
DE102007022565A1 (de) * 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
SG183049A1 (en) * 2007-07-20 2012-08-30 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101977905B (zh) 2008-01-23 2014-07-02 百时美施贵宝公司 4-吡啶酮化合物及其对于癌症的用途
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010069966A1 (en) * 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
KR101679642B1 (ko) 2009-04-30 2016-11-25 글락소 그룹 리미티드 Ｐｉ3­키나아제 억제제로서 옥사졸 치환된 인다졸
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
BR112012023021A2 (pt) * 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2835131B1 (en) * 2010-12-14 2017-09-06 Electrophoretics Limited Casein kinase 1delta (CK1delta) inhibitors
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2012340200B2 (en) 2011-11-17 2017-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-Terminal Kinase (JNK)
EP2797879B1 (en) * 2011-12-27 2018-12-26 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
CN103739550B (zh) * 2014-01-02 2016-06-01 中国药科大学 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
CA2937111A1 (en) * 2014-01-24 2015-07-30 Abbvie Inc. 6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
PE20170774A1 (es) * 2014-08-19 2017-07-04 Shanghai Haihe Pharmaceutical Co Ltd Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CN106279119B (zh) * 2015-05-27 2020-06-16 上海海和药物研究开发有限公司 一种新型激酶抑制剂的制备及其应用
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017068064A1 (en) * 2015-10-22 2017-04-27 Selvita S.A. Pyridone derivatives and their use as kinase inhibitors
CN105467027B (zh) * 2015-11-18 2021-09-21 北京万全德众医药生物技术有限公司 一种用气相色谱法分离测定米诺膦酸中间体有关物质的方法
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CA3069339A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
PE20201028A1 (es) 2017-08-01 2020-10-05 Theravance Biopharma Randd Ip Llc Compuestos biciclicos de pirazol y triazolo como inhibidores de las cinasas jak
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN110117278B (zh) * 2018-02-07 2022-07-19 石家庄以岭药业股份有限公司 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
WO2020086503A1 (en) * 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
EP3870589B1 (en) 2018-10-24 2023-09-06 Bristol-Myers Squibb Company Substituted indole dimer compounds
EP3914348A1 (en) 2019-01-23 2021-12-01 Theravance Biopharma R&D IP, LLC Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
CN115003666A (zh) * 2019-12-04 2022-09-02 先正达农作物保护股份公司 杀有害生物活性的稠合二环杂芳香族氨基化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133081A (en) * 1964-05-12 J-aminoindazole derivatives
US2971842A (en) * 1956-03-21 1961-02-14 Gen Aniline & Film Corp Light sensitive layers for photomechanical reproduction
GB965511A (en) * 1961-11-30 1964-07-29 Smith Kline French Lab Improvements in or relating to 3-aminoindazole derivatives
DE1280878B (de) * 1961-11-30 1968-10-24 Smith Kline French Lab 3-Aminoindazole
BE626284A (pt) * 1962-04-28
US3720671A (en) * 1970-10-05 1973-03-13 Ciba Geigy Ag Polycyclic dyestuffs
FR2111641A2 (en) * 1970-10-09 1972-06-09 Geigy Ag J R Polycyclic cpds as dispersion dyestuffs for - hydrophobic organic fibres
DE2458965C3 (de) * 1974-12-13 1979-10-11 Bayer Ag, 5090 Leverkusen 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPS51143010A (en) * 1975-06-04 1976-12-09 Kao Corp Stable bleaching detergent composition
SU742430A1 (ru) * 1978-11-09 1980-06-25 Предприятие П/Я А-7850 Способ получени 3-амино-5-нитроиндазола
JPS58159473A (ja) * 1982-03-17 1983-09-21 Asahi Chem Ind Co Ltd ベンゼン環置換基を有する新規な１位置換インダゾ−ル誘導体およびその製造法
EP0090972B1 (en) * 1982-03-17 1990-05-30 Asahi Kasei Kogyo Kabushiki Kaisha Indazole derivatives
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸

Also Published As

Publication number Publication date
AU2003242809A1 (en) 2003-09-29
UY27713A1 (es) 2003-09-30
PL370478A1 (en) 2005-05-30
MEP16108A (en) 2010-06-10
US6949579B2 (en) 2005-09-27
JP2005530711A (ja) 2005-10-13
JO2326B1 (en) 2006-06-28
PE20040155A1 (es) 2004-04-18
CN1656078A (zh) 2005-08-17
RU2004129780A (ru) 2005-04-10
AR038915A1 (es) 2005-02-02
AU2003242809B2 (en) 2010-03-18
ME00058B (me) 2010-10-10
CA2478542C (fr) 2012-02-21
MA27230A1 (fr) 2005-02-01
FR2836915B1 (fr) 2008-01-11
MXPA04007478A (es) 2004-11-10
RS79504A (en) 2006-12-15
NO20044137L (no) 2004-11-25
JP2010222357A (ja) 2010-10-07
EP1487804B1 (fr) 2014-02-26
SV2003001494A (es) 2003-07-10
AU2003242809B8 (en) 2010-04-15
MY138269A (en) 2009-05-29
IL163831A (en) 2010-12-30
IL163831A0 (en) 2005-12-18
KR20040091121A (ko) 2004-10-27
TWI329103B (en) 2010-08-21
EP1487804A2 (fr) 2004-12-22
FR2836915A1 (fr) 2003-09-12
NZ535147A (en) 2007-08-31
CN101962365A (zh) 2011-02-02
BR0308373A (pt) 2005-01-11
RS52396B (en) 2013-02-28
JP5315287B2 (ja) 2013-10-16
KR101068770B1 (ko) 2011-09-30
HRP20040824A2 (en) 2005-06-30
CA2478542A1 (fr) 2003-09-25
US20040014802A1 (en) 2004-01-22
JP4648630B2 (ja) 2011-03-09
GT200300057A (es) 2006-10-19
WO2003078403A3 (fr) 2004-04-22
ZA200406687B (en) 2005-10-26
RU2345070C2 (ru) 2009-01-27
TW200403226A (en) 2004-03-01
PA8568301A1 (es) 2005-02-04
HRP20040824B1 (hr) 2013-05-31
WO2003078403A2 (fr) 2003-09-25

Similar Documents

Publication Publication Date Title
NO329384B1 (no) Aminoindazolderivater, fremstilling derav samt farmasoytiske preparater og medisinske produkter inneholdende forbindelsene
JP3346437B2 (ja) 複素環化合物
AU2001279089B2 (en) Indazole derivatives as jnk inhibitors
CA2542609C (en) Novel indazole derivatives
JP3697486B2 (ja) ブラジキニン拮抗剤としての、ピリドピリミドン類、キノリン類および縮合ｎ−複素環類
CA2596527C (en) Igf-1r inhibitors
AU2004232981A1 (en) Indazole derivatives as JNK inhibitors
SG182187A1 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
AU2001279089A1 (en) Indazole derivatives as JNK inhibitors
JP2000502330A (ja) メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用、ならびにそれらの製造に有用な方法および中間体
EP3860636A1 (en) Matriptase 2 inhibitors and uses thereof

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees